Health
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
WILMINGTON, Del., October 18, 2025--Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate. The trial compared ENHERTU followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patie
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/6c1e94e62d5d87e2214d881d08d22e83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qT6xdGmXQTxhjhiDqN0TBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6c1e94e62d5d87e2214d881d08d22e83","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TyRmQ3Auxp4GIYxapgAaTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/6c1e94e62d5d87e2214d881d08d22e83","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favorable safety profile vs. standard treatment","length":182,"tagName":"p","attribs":{}},{"type":"text","content":"DESTINY-Breast11 presented in ESMO Presidential Symposium alongside DESTINY-Breast05 reinforce potential for AstraZeneca and Daiichi Sankyo’s ENHERTU to become a foundational treatment in curative-intent early breast cancer setting","length":231,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., October 18, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate. The trial compared ENHERTU followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.","length":740,"tagName":"p"},{"type":"text","content":"In DESTINY-Breast11, ENHERTU followed by THP resulted in a pCR rate of 67.3% compared with 56.3% for ddAC-THP, representing a pCR rate improvement of 11.2%. Improvement in pCR rates was observed across both hormone receptor (HR)-positive and HR-negative subgroups (HR-positive: 6...